Locally Advanced Urothelial Carcinoma Clinical Trials

6 recruiting

Locally Advanced Urothelial Carcinoma Trials at a Glance

6 actively recruiting trials for locally advanced urothelial carcinoma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Atlanta, Jacksonville, and Anaconda. Lead sponsors running locally advanced urothelial carcinoma studies include Mayo Clinic, Beijing Biotech, and Emory University.

Browse locally advanced urothelial carcinoma trials by phase

Treatments under study

About Locally Advanced Urothelial Carcinoma Clinical Trials

Looking for clinical trials for Locally Advanced Urothelial Carcinoma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Urothelial Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Urothelial Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 3

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
National Cancer Institute (NCI)320 enrolled129 locationsNCT06524544
Recruiting
Phase 1

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma+1 more
Emory University32 enrolled1 locationNCT04878029
Recruiting
Phase 1

Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma

Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+2 more
Beijing Biotech42 enrolled1 locationNCT07492628
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Phase 2

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

Locally Advanced Urothelial CarcinomaOligo-metastaic Urothelial Carcinoma
Yale University32 enrolled1 locationNCT07048457